What is the P/E ratio of Danimer Scientific 2024?
The Danimer Scientific P/E ratio is -0.36.
3 years
5 years
10 years
25 Years
Max
Gain insights into Danimer Scientific, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Danimer Scientific from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Danimer Scientific’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Danimer Scientific. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Danimer Scientific’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Danimer Scientific’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Danimer Scientific’s growth potential.
Date | Danimer Scientific Revenue | Danimer Scientific EBIT | Danimer Scientific Net Income |
---|---|---|---|
2029e | 637.5 M undefined | 0 undefined | 54.18 M undefined |
2028e | 529.65 M undefined | 78.49 M undefined | 60.2 M undefined |
2027e | 386.04 M undefined | 8.16 M undefined | -42.14 M undefined |
2026e | 302.94 M undefined | -28.76 M undefined | -78.25 M undefined |
2025e | 140.13 M undefined | -33.5 M undefined | -66.82 M undefined |
2024e | 77.01 M undefined | -67.16 M undefined | -107.6 M undefined |
2023 | 46.68 M undefined | -125.19 M undefined | -155.47 M undefined |
2022 | 53.22 M undefined | -123.94 M undefined | -179.76 M undefined |
2021 | 58.75 M undefined | -99.39 M undefined | -60.11 M undefined |
2020 | 47.33 M undefined | -15.74 M undefined | -8.85 M undefined |
2019 | 0 undefined | 0 undefined | 0 undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2019 | 0 USD | 0 USD | 0 USD |
2020 | 47.33 M USD | -15.74 M USD | -8.85 M USD |
2021 | 58.75 M USD | -99.39 M USD | -60.11 M USD |
2022 | 53.22 M USD | -123.94 M USD | -179.76 M USD |
2023 | 46.68 M USD | -125.19 M USD | -155.47 M USD |
2024e | 77.01 M USD | -67.16 M USD | -107.6 M USD |
2025e | 140.13 M USD | -33.5 M USD | -66.82 M USD |
2026e | 302.94 M USD | -28.76 M USD | -78.25 M USD |
2027e | 386.04 M USD | 8.16 M USD | -42.14 M USD |
2028e | 529.65 M USD | 78.49 M USD | 60.2 M USD |
2029e | 637.5 M USD | 0 USD | 54.18 M USD |
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e |
---|---|---|---|---|---|---|---|---|---|---|
0 | 47 | 58 | 53 | 46 | 77 | 140 | 302 | 386 | 529 | 637 |
- | - | 23.40 | -8.62 | -13.21 | 67.39 | 81.82 | 115.71 | 27.81 | 37.05 | 20.42 |
- | 25.53 | 3.45 | -13.21 | -52.17 | - | - | - | - | - | - |
0 | 12 | 2 | -7 | -24 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | -15 | -99 | -123 | -125 | -67 | -33 | -28 | 8 | 78 | 0 |
- | -31.91 | -170.69 | -232.08 | -271.74 | -87.01 | -23.57 | -9.27 | 2.07 | 14.74 | - |
0 | -8 | -60 | -179 | -155 | -107 | -66 | -78 | -42 | 60 | 54 |
- | - | 650.00 | 198.33 | -13.41 | -30.97 | -38.32 | 18.18 | -46.15 | -242.86 | -10.00 |
25 | 84.54 | 93.08 | 101.1 | 102 | 0 | 0 | 0 | 0 | 0 | 0 |
- | - | - | - | - | - | - | - | - | - | - |
The Danimer Scientific Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Danimer Scientific is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Danimer Scientific's sales revenue. A higher gross margin percentage indicates that the Danimer Scientific retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Danimer Scientific's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Danimer Scientific's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Danimer Scientific's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Danimer Scientific. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Danimer Scientific's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Danimer Scientific Gross margin | Danimer Scientific Profit margin | Danimer Scientific EBIT margin | Danimer Scientific Profit margin |
---|---|---|---|
2029e | -52.09 % | 0 % | 8.5 % |
2028e | -52.09 % | 14.82 % | 11.37 % |
2027e | -52.09 % | 2.11 % | -10.92 % |
2026e | -52.09 % | -9.49 % | -25.83 % |
2025e | -52.09 % | -23.91 % | -47.68 % |
2024e | -52.09 % | -87.2 % | -139.72 % |
2023 | -52.09 % | -268.15 % | -333.03 % |
2022 | -14.86 % | -232.88 % | -337.77 % |
2021 | 4.77 % | -169.17 % | -102.31 % |
2020 | 27.17 % | -33.26 % | -18.7 % |
2019 | -52.09 % | 0 % | 0 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2019 | -52.09 % | 0 % | 0 % |
2020 | 27.17 % | -33.26 % | -18.7 % |
2021 | 4.77 % | -169.17 % | -102.31 % |
2022 | -14.86 % | -232.88 % | -337.77 % |
2023 | -52.09 % | -268.15 % | -333.03 % |
2024e | -52.09 % | -87.2 % | -139.72 % |
2025e | -52.09 % | -23.91 % | -47.68 % |
2026e | -52.09 % | -9.49 % | -25.83 % |
2027e | -52.09 % | 2.11 % | -10.92 % |
2028e | -52.09 % | 14.82 % | 11.37 % |
2029e | -52.09 % | 0 % | 8.5 % |
3 years
5 years
10 years
25 Years
Max
Revenue per share represents the total revenue Danimer Scientific earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Danimer Scientific's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Danimer Scientific’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Danimer Scientific's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Date | Danimer Scientific Sales per Share | Danimer Scientific EBIT per share | Danimer Scientific Earnings per Share |
---|---|---|---|
2029e | 5.4 undefined | 0 undefined | 0.46 undefined |
2028e | 4.49 undefined | 0 undefined | 0.51 undefined |
2027e | 3.27 undefined | 0 undefined | -0.36 undefined |
2026e | 2.57 undefined | 0 undefined | -0.66 undefined |
2025e | 1.19 undefined | 0 undefined | -0.57 undefined |
2024e | 0.65 undefined | 0 undefined | -0.91 undefined |
2023 | 0.46 undefined | -1.23 undefined | -1.52 undefined |
2022 | 0.53 undefined | -1.23 undefined | -1.78 undefined |
2021 | 0.63 undefined | -1.07 undefined | -0.65 undefined |
2020 | 0.56 undefined | -0.19 undefined | -0.1 undefined |
2019 | 0 undefined | 0 undefined | 0 undefined |
Sales per Share | EBIT per share | Earnings per Share | |
---|---|---|---|
2019 | 0 USD | 0 USD | 0 USD |
2020 | 0.56 USD | -0.19 USD | -0.1 USD |
2021 | 0.63 USD | -1.07 USD | -0.65 USD |
2022 | 0.53 USD | -1.23 USD | -1.78 USD |
2023 | 0.46 USD | -1.23 USD | -1.52 USD |
2024e | 0.65 USD | 0 USD | -0.91 USD |
2025e | 1.19 USD | 0 USD | -0.57 USD |
2026e | 2.57 USD | 0 USD | -0.66 USD |
2027e | 3.27 USD | 0 USD | -0.36 USD |
2028e | 4.49 USD | 0 USD | 0.51 USD |
2029e | 5.4 USD | 0 USD | 0.46 USD |
3 years
5 years
10 years
25 Years
Max
Revenue per share represents the total revenue Danimer Scientific earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Danimer Scientific's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Danimer Scientific’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Danimer Scientific's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Number of stocks | |
---|---|
2019 | 25 M Aktien |
2020 | 84.54 M Aktien |
2021 | 93.08 M Aktien |
2022 | 101.1 M Aktien |
2023 | 102 M Aktien |
2024e | 102 M Aktien |
2025e | 102 M Aktien |
2026e | 102 M Aktien |
2027e | 102 M Aktien |
2028e | 102 M Aktien |
2029e | 102 M Aktien |
Date | EPS Estimate | EPS Actual | Quarterly report |
---|---|---|---|
3/31/2024 | -0.27 | -0.26 (2.59 %) | 2024 Q1 |
12/31/2023 | -0.39 | -0.39 (0.18 %) | 2023 Q4 |
9/30/2023 | -0.35 | -0.39 (-12.46 %) | 2023 Q3 |
6/30/2023 | -0.37 | -0.38 (-2.45 %) | 2023 Q2 |
3/31/2023 | -0.39 | -0.36 (7.36 %) | 2023 Q1 |
12/31/2022 | -0.29 | -0.28 (4.24 %) | 2022 Q4 |
9/30/2022 | -0.18 | -0.94 (-425.73 %) | 2022 Q3 |
6/30/2022 | -0.24 | -0.3 (-22.55 %) | 2022 Q2 |
3/31/2022 | -0.24 | -0.26 (-9.61 %) | 2022 Q1 |
12/31/2021 | -0.3 | -0.34 (-12.36 %) | 2021 Q4 |
Scope 1 - Direct Emissions | — |
Scope 2 - Indirect emissions from purchased energy | — |
Scope 3 - Indirect emissions within the value chain | — |
Total CO₂ emissions | — |
CO₂ reduction strategy | ✅ |
Coal energy | ❌ |
Nuclear power | ❌ |
Animal experiments | ❌ |
Fur & Leather | — |
Pesticides | — |
Palm Oil | — |
Tobacco | ❌ |
Genetically modified organisms | ❌ |
Climate concept | — |
Sustainable forestry | — |
Recycling regulations | ❌ |
Environmentally friendly packaging | ❌ |
Hazardous substances | ❌ |
Fuel consumption and efficiency | ❌ |
Water consumption and efficiency | ❌ |
Percentage of female employees | — |
Percentage of women in management | — |
Percentage of Asian employees | — |
Share of Asian management | — |
Percentage of Hispanic/Latino employees | — |
Hispano/Latino Management share | — |
Percentage of Black employees | — |
Black Management Share | — |
Percentage of white employees | — |
White Management Share | — |
Adult content | ❌ |
Alcohol | ❌ |
Weapons | — |
Firearms | ❌ |
Gambling | ❌ |
Military contracts | ❌ |
Human rights concept | ❌ |
Privacy concept | — |
Occupational health and safety | ❌ |
Catholic | ✅ |
Environmental reporting | ❌ |
Stakeholder Engagement | ❌ |
Call Back Policies | ❌ |
Antitrust law | ❌ |
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
% | Name | Stocks | Change | Date |
---|---|---|---|---|
9.53 % | Armistice Capital LLC | 11,250,000 | 11,250,000 | 3/29/2024 |
4.81 % | BlackRock Institutional Trust Company, N.A. | 5,677,740 | 379,222 | 12/31/2023 |
4.25 % | The Vanguard Group, Inc. | 5,020,156 | -4,826 | 12/31/2023 |
3.85 % | Croskrey (Stephen E) | 4,548,587 | 251,506 | 3/29/2024 |
3.21 % | Calhoun (Philip Gregory) | 3,785,295 | 0 | 3/29/2024 |
2.32 % | Greenlight Capital, Inc. | 2,734,580 | 131,890 | 12/31/2023 |
2.15 % | Jefferies LLC | 2,541,946 | 991,000 | 12/31/2023 |
1.59 % | Geode Capital Management, L.L.C. | 1,876,486 | 67,139 | 12/31/2023 |
1.55 % | State Street Global Advisors (US) | 1,834,118 | -19,395 | 12/31/2023 |
1.38 % | Invesco Advisers, Inc. | 1,626,402 | -180,351 | 12/31/2023 |
The Danimer Scientific P/E ratio is -0.36.
The Danimer Scientific P/S ratio is 0.51.
The AlleAktien quality score for Danimer Scientific is 3/10.
The expected Danimer Scientific revenue is 77.01 M USD.
The expected Danimer Scientific profit is -107.6 M USD.
No history available for Danimer Scientific.
Danimer Scientific pays a dividend of 0 USD distributed over payouts per year.
The dividend cannot currently be calculated for Danimer Scientific or the company does not pay out a dividend.
The ISIN of Danimer Scientific is US2362721001.
The WKN of Danimer Scientific is A2QHQZ.
The ticker of Danimer Scientific is DNMR.
Over the past 12 months, Danimer Scientific paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Danimer Scientific is expected to pay a dividend of 0 USD.
The current dividend yield of Danimer Scientific is .
Danimer Scientific pays a quarterly dividend. This is distributed in the months of .
Danimer Scientific paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Danimer Scientific is assigned to the 'Commodities' sector.
To receive the latest dividend of Danimer Scientific from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
The last dividend was paid out on 7/31/2024.
In the year 2023, Danimer Scientific distributed 0 USD as dividends.
The dividends of Danimer Scientific are distributed in USD.
Stock Exchange | Danimer Scientific Ticker |
---|---|
DÜSSELDORF | 6CU.DU |
FRANKFURT | 6CU.F |
MUNICH | 6CU.MU |
NEW YORK | DNMR |
Danimer Scientific Ticker | Danimer Scientific FIGI |
---|---|
DNMR:US | BBG00S4VMQT2 |
DNMR:UA | BBG00V1L4CM8 |
DNMR:UC | BBG00V1L4CN7 |
DNMR:UN | BBG00V1L4CQ4 |
DNMR:UP | BBG00V1L4CR3 |
DNMR:UB | BBG00V1L4CT1 |
DNMR:UT | BBG00V1L4CV8 |
DNMR:UM | BBG00V1L4CW7 |
DNMR:UX | BBG00V1L4CX6 |
DNMR:UD | BBG00V1L4D28 |
DNMR:UF | BBG00V1L4D55 |
DNMR:VY | BBG00V1L4D64 |
DNMR:VJ | BBG00V1L4D73 |
DNMR:VK | BBG00V1L4D82 |
DNMR:VF | BBG00V1L4D91 |
DNMR*:MM | BBG00Z1WHN74 |
DNMR*:MF | BBG00Z1WHN83 |
DNMR*:MU | BBG00Z1WHN92 |
6CU:GR | BBG0141YN8N6 |
6CU:GF | BBG0141YN8P4 |
6CU:GD | BBG0141YN8Q3 |
6CU:GS | BBG0141YN8S1 |
6CU:GM | BBG0141YN8T0 |
6CU:GB | BBG0141YN8W6 |
6CU:GZ | BBG0141YQNW0 |
DNMREUR:XS | BBG01420V4M0 |
DNMREUR:X2 | BBG01420V4P7 |
DNMREUR:XH | BBG01420V4S4 |
DNMREUR:XF | BBG01420V4V0 |
DNMREUR:XE | BBG01420V4X8 |
DNMREUR:XJ | BBG01420V4Z6 |
DNMREUR:XL | BBG01420V501 |
DNMREUR:XG | BBG01420V510 |
DNMREUR:XO | BBG01420V529 |
DNMREUR:XA | BBG01420V574 |
DNMREUR:E1 | BBG01420V583 |
DNMREUR:XT | BBG01420V592 |
DNMREUR:XW | BBG01420V5B9 |
DNMREUR:XU | BBG01420V5D7 |
DNMREUR:XV | BBG01420V5G4 |
DNMREUR:XM | BBG01420V5H3 |
DNMREUR:XQ | BBG01420V5J1 |
DNMREUR:XX | BBG01420V5K9 |
DNMREUR:XZ | BBG01420V5M7 |
DNMREUR:X1 | BBG01420V5P4 |
DNMREUR:EU | BBG01420V6C6 |
DNMRGBP:XS | BBG01430JR42 |
DNMRGBP:X2 | BBG01430JR51 |
DNMRGBP:XH | BBG01430JR79 |
DNMRGBP:XF | BBG01430JR97 |
DNMRGBP:XE | BBG01430JRC3 |
DNMRGBP:XJ | BBG01430JRD2 |
DNMRGBP:XL | BBG01430JRF0 |
DNMRGBP:XG | BBG01430JRG9 |
DNMRGBP:XO | BBG01430JRH8 |
DNMRGBP:XA | BBG01430JRM2 |
DNMRGBP:E1 | BBG01430JRN1 |
DNMRGBP:XT | BBG01430JRP9 |
DNMRGBP:XW | BBG01430JVY0 |
DNMRGBP:XU | BBG01430JVZ9 |
DNMRGBP:XV | BBG01430JW14 |
DNMRGBP:XM | BBG01430JW23 |
DNMRGBP:XQ | BBG01430JW41 |
DNMRGBP:XX | BBG01430JZD4 |
DNMRGBP:XZ | BBG01430JZH0 |
DNMRGBP:X1 | BBG01430JZK6 |
DNMRGBP:EU | BBG01430KHZ8 |
DNMRUSD:XS | BBG01457TM72 |
DNMRUSD:X2 | BBG01457TM90 |
DNMRUSD:XH | BBG01457TMC6 |
DNMRUSD:XF | BBG01457TMF3 |
DNMRUSD:XE | BBG01457TMH1 |
DNMRUSD:XJ | BBG01457TMJ9 |
DNMRUSD:XL | BBG01457TML6 |
DNMRUSD:XG | BBG01457TMM5 |
DNMRUSD:XO | BBG01457TMN4 |
DNMRUSD:XA | BBG01457TMS9 |
DNMRUSD:E1 | BBG01457TMT8 |
DNMRUSD:XT | BBG01457TMV5 |
DNMRUSD:XW | BBG01457TMW4 |
DNMRUSD:XU | BBG01457TMX3 |
DNMRUSD:XV | BBG01457TMZ1 |
DNMRUSD:XM | BBG01457TN07 |
DNMRUSD:XQ | BBG01457TN16 |
DNMRUSD:XX | BBG01457TN25 |
DNMRUSD:XZ | BBG01457TN34 |
DNMRUSD:X1 | BBG01457TN52 |
DNMRUSD:EU | BBG01457TNG0 |
6CU:TH | BBG0146X6KF4 |
6CU:LA | BBG018HG7V83 |
6CU:LU | BBG018J83L76 |
6CU:QT | BBG01FPF4XY0 |
Our stock analysis for Danimer Scientific Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Danimer Scientific Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.